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Abstract 
Cryptolepine, the main alkaloid present in the roots of Cryptolepis sanguinolenta, presents a large spectrum of 
biological properties. It has been reported to behave like a DNA intercalator with a preference for GC-rich 
sequences. In this study, dialysis competition assay and mass spectrometry experiments were used to determine 
the affinity of cryptolepine and neocryptolepine for DNA structures among duplexes, triplexes, quadruplexes and 
single strands. Our data confirm that cryptolepine and neocryptolepine prefer GC over AT-rich duplex 
sequences, but also recognize triplex and quadruplex structures. These compounds are weak telomerase 
inhibitors and exhibit a significant preference for triplexes over quadruplexes or duplexes. 
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1. Introduction 
Cryptolepine (5-methyl indolo[2,3b]-quinoline, Fig. 1A, left), a natural alkaloid, was first isolated from the roots 
of Cryptolepis triangularis [1-3]. This compound is the main alkaloid present in the roots of Cryptolepis 
sanguinolenta, a plant traditionally used in Central and West Africa for the treatment of rheumatism, urinary and 
respiratory infections. Extracts of the roots are used in decoction to treat fevers due to malaria and stomach 
disorders [4]. Cryptolepine presents a large spectrum of biological properties, including hypotensive and 
antipyretic, antimuscarinic, antibacterial and antiinflammatory effects [5]. It also possesses potent activity in 
vitro against Plasmodium falciparum, which is one of the main parasite species responsible for malaria. The 
mechanism of action of this antimalarial product remains unclear; at least two independent effects may together 
lead to a potent activity. First, it behaves like a DNA intercalator with a preference for GC-rich sequences [5]. 
Second, it may act like chloroquin by inhibiting the detoxification of haeme in red blood cells [6]. It has been 
proposed that crytolepine exerts its cytotoxic action via the inhibition of DNA synthesis and stabilization of 
topoisomerase II-DNA covalent complexes [5]. Neocryptolepine differs from the parent isomer only in terms of 
the orientation of the indole unit with respect to the quinoline moiety (see Fig. 1 A, right). It also intercalates into 
GC-rich sequences and interferes with the catalytic activity of human topoisomerase II, although less efficiently 
than cryptolepine [7]. Cryptolepine and neocryptolepine have cytotoxic effects and induce apoptosis in HL60 
leukaemia cells [8]. Recently, the structure of a cryptolepine-DNA complex was elucidated by X-ray 
crystallography. Lisgarten et al. [9] demonstrated that the drug interacts with the CC sites of the d(CCTAGG)2 
oligonucleotide; this is the first intercalator to bind non-alterning (pyrimidine-pyrimidine) DNA sequence [9]· 
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Fig. 1. (A) Formulae of cryptolepine (5-methyl indolo[2,3b]-quinoline, left), neocryptolepine (R = H) and 
derivatives (R = Cl, Br and OCH3) (right). (B) T.A*T triplet (left) and a schematic diagram of an 
oligo(dA)/2oligo(dT) triple-helix, showing the relative orientation of the strands. (C) G-quartet (left) and a 
schematic diagram of intramolecular antiparallel G-quadruplexes involving three quartets. 
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The binding mode of these derivatives to double-stranded DNA has been extensively studied. However, besides 
duplexes, DNA is prone to structural polymorphism and a number of alternative DNA structures have been 
described to date. DNA conformation may differ from a regular double-helix and may involve the association of 
more than two strands, leading to the formation of triplexes and quadru-plexes. Alternative DNA structures offer 
significant differences in terms of electrostatics, shape and rigidity compared to single- or double-stranded DNA. 
Therefore, specific recognition of unusual DNA structures, such as triplexes and quadruplexes by small 
molecules should be possible. 
Short oligonucleotides can bind to the major groove of DNA duplexes to form a triple helix (Fig. 1B) [10,11]. 
Triplex-forming oligonucleotides (TFOs) can interfere with the binding of proteins [12] and affect the 
transcription of a specific gene [13]. At least three classes of triplexes exist which differ in sequence composition 
and relative orientations of the phosphodiester backbone of the third strand [14]. Nevertheless, triplex stability 
under physiological conditions is relatively low and this limitation led to the design of small molecules that 
interact with the triplex and stabilize it [15] or of chemical modifications that increase the affinity of the third 
strand for its target [16]. 
G-quadruplexes are a family of secondary DNA structures formed in the presence of monovalent cations that 
consist of four-stranded structures stabilized by G-quartets (Fig. 1C). There is a renewed interest in G-
quadruplex structures due to their putative biological regulatory function [17,18]. The 3' terminal region of the 
G-rich strand of human telomeres is single-stranded and may adopt a G-quadruplex conformation [19]. This 
structure has been shown to directly inhibit telom-erase elongation in vitro [20]. Telomeres protect chromosomal 
ends from fusion events and provide a means for complete replication of the chromosome. Telomerase is 
expressed in tumour cells, but not in most somatic cells. Therefore, a drug that stabilizes quadruplexes could 
interfere with telomere elongation and replication of cancer cells. The recent discovery of positively charged 
aromatic compounds (for a review [21]) that interact with G-quartet led us to test the binding of cryptolepine and 
neocryptolepine analogues to G-quadruplexes. A cytidine-rich oligomer forms a radically different quadruplex in 
which two parallel C-strands associate in a head-to-tail orientation with their C●C+ pairs face-to-face, 
intercalated in a so called i-motif or C-quadruplex [22,23]. 
The aim of the present work is to study the binding and/or stabilization of cryptolepine and its regio selective 
isomer neocryptolepine to a panel of different DNA structures. Dialysis competition assay and mass 
spectrometric experiments were used to determine the affinity of cryptolepine for different DNA structures 
(duplexes, triplexes, quadruplexes and single strands). Our data confirm that cryptolepine prefers GC over AT-
rich duplex sequences, but also recognizes triplex and quadruplex structures. In order to strengthen these results, 
we performed UV and fluorescence melting experiments. Finally, we studied the effect of these compounds on 
telomerase activity by a telomerase repeat amplification protocol (TRAP) assay. 
2. Materials and methods 
2.1.  Compounds 
Cryptolepine was isolated from Cryptolepis sanguino-lenta [24]. Neocryptolepine (as well as 2-C1-, 2-Br- and 2 
methoxyneocryptolepine) was obtained by organic synthesis as previously described [25]. Powders were 
resuspended at high concentrations (mM) in DMSO (Sigma) and then diluted in bidistilled water for further 
experiments. The compounds were evaluated as their hydrochloride salt. 
2.2.  Nucleic acids 
Oligodeoxynucleotide probes were synthesized by Euro-gentec (Belgium) on the 1 µmol scale. Purity was 
checked by gel electrophoresis. All the concentrations were expressed in strand molarity using a nearest-
neighbour approximation for the absorption coefficients of the unfolded species. All polynucleotides were 
ordered from Amersham-Pharmacia. F21MB is a doubly labelled 21 base-long oligomer that mimics the human 
telomeric guanine-rich strand with fluorescein at the 5' endandDABCYL at the 3' end, respectively. It was 
synthesized and purified by Eurogentec (Belgium). 
2.3.  Dialysis experiments 
The initial dialysis protocol was defined by Ren and Chaires [26]. We have adapted this test to accommodate a 
different set of nucleic acid structures [27]. Briefly, a buffer consisting of 15 mM sodium cacodylate (pH 6.5), 
10 mM MgCl2, and 185 mM NaCl was used for all the experiments. All structures used in these experiments 
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were stable at room temperature under the chosen experimental conditions [28]. In particular, the presence of 
185 mM sodium chloride promotes quadruplex formation: the melting temperature of the quadruplexes was 
found to be 62 °C for the human telomeric motif and > 90 °C for the parallel quadruplex [28]. 400 ml of the 
dialysate solution containing 1 µM ligand were used for each competition dialysis assay. A volume of 200 µl at 
75 µM monomelic unit (nucleotide, base pair, base triplet or quartet) of each of the nucleic acids samples was 
pipetted into a separate Dialyzer unit (Pierce). All 19 dialysis units were then placed in the beaker containing the 
dialysate solution. The beaker was covered with Parafilm and wrapped in foil, and its contents were allowed to 
equilibrate with continuous stirring at room temperature (20-22 °C) overnight. At the end of the equilibration 
period, DNA samples were carefully removed to microfuge tubes, and treated with 1% SDS. The ligand 
concentration in each sample was determined by fluorescence spectroscopy (excitation at 320 nm for 
cryptolepine and neocryptolepine). The amount of dye in each dialysis unit is directly proportional to the 
fluorescence emission intensity signal of the sample as the nucleic acid-compound complex is dissociated by 
SDS. This quantification procedure has been validated in a number of independent studies by several groups, 
including ours [26,28-31]. 
A panel of 19 different nucleic acid structures were used (Table 1). They have been described in detail elsewhere 
[27,28]. The TC, GA and GT triplexes result from the association of two strands of different lengths (13 and 30 
nucleotides) [14]. The GA duplex results from the self-association of a (GA)12 oligonucleotide. The parallel-
stranded psD duplex results from the association of two AT strands. The 24CTG mimics eight repeats of the 
trinucleotide unit (CTG)8. ds26 is a duplex formed with a self-complementary oligonucleotide. 22CT is an 
oligonucleotide that mimics the cytosine-rich strand of human telomeres [32], whereas 22AG is an 
oligonucleotide that mimics the guanine-rich strand of human telomeres. 24G20 may form an intermolecular G-
quadruplex, whereas poly(dC) may form an intermolecular i-motif. Single strands DNA are represented by 
poly(dT) and poly(dA). Poly (rU) and poly(rA) represent single-stranded RNA. 
 
Table 1. List of the oligonucleotides used in this study 
Triplex 14C3 5'-TTCTTCTTTTTTCT-3'
5'-GATACGAGTTAAGAAGAAAAAAGATTGAGCTGATAG-3' 




(G,A) triplex TT-GGAGGAGAGAAAG-3' 
CC-GGAGGAGAGAAAG-5' 
5'-CCTCCTCTCTTTC-3' 
(G,T) triplex TT-GGTGGTGTGTTTG-3' 
CC-GGAGGAGAGAAAG-5' 
5'-CCTCCTCTCTTTC-3' 
24GA (parallel duplex) 5'-GAGAGAGAGAGAGAGAGAGAGAGA-3' 
PSD (parallel duplex) 5'-AAAAAAAAAATAATTTTAAATATT-3' 
5.TTTTTTTTTTATTAAAATTTATAA-3' 
24CTG (trinucleotide repeat) 3'-GTCGTCGTCGTCGTCGTCGTCGTC-5' 
DS26 (intramolecular duplex) 3'-GTTAGCCTAGCTTAAGCTAGGCTAAC-5' 
22CT (intramolecular i-motif) 5'-CCCTAACCCTAACCCTAACCCT-3' 
22AG (intramolecular G-quartet) 5'-AGGGTTAGGGTTAGGGTTAGGG-3' 
24G20 (intermolecular G-quartet) 5'-TTGGGGGGGGGGGGGGGGGGGGTT-3' 
 
Published in : Biochimie (2003), vol. 85, pp. 535-547. 
Status : Postprint (Author’s Version) 
2.4. Mass spectrometry 
Single-stranded oligodeoxyribonucleotides d(CG-TAAATTTACG) (MW = 3644.45), d(CGCGAATTCGCG) 
(MW =  3646.44  Da),  d(CGCGGGCCCGCG)  (MW  = 3678.40), d(TGGGGT) (M = 1863.26), d(GGGG-
TTTTGGGG) (MW = 3788.50), d((GGGTTA)3GGG) (MW = 6653.35), d(CCTTTTCTCTTTCC) (MW = 
4106.71), d(G-GAAAGAGAAAAGG) (MW = 4418.96), d(CCTTT-CTCTTTTCC) (MW = 4106.71) were 
purchased from Euro-gentec (Belgium) and used without further purification. Duplex and quadruplex solutions 
were prepared, respectively, in 100 and 150 mM NH4OAc, pH 7.0. The triple helix solution involves the 
association of three independent strands (5'dCCTTTTCTCTTTCC, 5'dGGAAAGAGAAAAGG and 
5'dCCTTTCTCTTTTCC)12 and was prepared in 150 mM NH4OAc acidified with acetic acid (pH 5.5). 
Oligonucleotide solutions were heated to 85 °C for 5 min and then slowly cooled down to 20 °C to form the 
desired duplex, quadruplex or triplex structures. The extinction coefficients for the unfolded single strands were 
provided by the supplier. Circular dichroism and UV melting experiments were used to characterize the solution 
conformation of the oligonucleotide in ammonium acetate [33]. Experiments on the duplex structures were 
performed on an LCQ mass spectrometer (Finnigan, Can Jose, CA, USA) as described previously [34]. Similar 
results are obtained on the Q-TOF instrument. Experiments on the quadruplexes and triplexes were performed on 
a Q-TOF Ultima Global apparatus (Micromass, Manchester, UK) operated in the negative ion mode. The 
experimental conditions were optimized for the Z-spray source to avoid denaturation of the duplex, triplex or 
quadruplex species. The source parameters are slightly different from those used on the Q-TOF2 instrument used 
previously [33] : a source block temperature of 70 °C and a cone voltage of 75 V were used. An RF Lens 1 
energy of 12 V (quadruplexes) and 20 V for triplexes and a source pressure of 2.8 mBar were necessary to 
observe fully desolvated complex species. Spectra of mixtures of DNA (C = 5 µM) + (neo)cryptolepine (C = 10 
µM) were recorded. Methanol (15%) was added to the samples just before injection in order to obtain a stable 
electrospray signal. The rate of sample infusion into the mass spectrometers was 4 µl/min. As previously 
discussed [34], the relative intensities of the free and bound DNA in the mass spectra are assumed to be 
proportional to the relative abundances of these species in solution. As the starting concentrations are known, the 
concentrations of all individual species at equilibrium (free DNA, 1:1 complex, 2:1 complex and, by difference, 
the free drug) can be determined from the relative intensities of the free DNA and the complexes, and the 
equilibrium binding constants can be determined. The affinity of the ligand for the DNA structure can also be 
characterized by the concentration of bound ligand per DNA molecule, or per binding unit. The concentration of 
bound ligand per DNA molecule is obtained with the following Eq. (1): 
  (1) 
where C0 is the starting DNA concentration, IDNA is the relative intensity of the DNA, and I(n:1)'s are relative 
intensities of the complexes (n drug molecules bound to 1 DNA target). The relative intensities were obtained 
from a sum of 60 spectra. The amount of bound ligand expressed in molecular binding unit (base pairs, base 
triplet or quartet in the DNA target) is determined by dividing the total amount of bound ligand by the number of 
monomelic units. 
2.5. FRET studies 
FRET can be used to probe the secondary structure of oligodeoxynucleotides mimicking repeats of the guanine-
rich strand of vertebrate telomeres, provided that a fluorescein molecule (donor) and a DABCYL derivative 
(quencher) are attached to the 5' and 3' ends of the oligonucleotide, respectively. FRET measurements with the 
F21MB oligonucleotide were performed on a Spex Fluorolog DM IB instrument, using a bandwidth of 1.8 nm 
and 0.2 x 1 cm quartz cuvettes, containing 600 µl of solution in a 0.1 M lithium chloride, 10 mM sodium pH 7.2 
cacodylate buffer [35]. Other buffers have been tested to demonstrate that a weak stabilization is still observed 
under different experimental conditions. The temperature of the circulating water bath was recorded at regular 
time intervals. The melting of the G-quadruplex was monitored in the presence and or in the absence of the dye 
by measuring the fluorescence of the donor. A concentration of 1-3 µM of cryptolepine derivatives was chosen. 
2.6.  UV-melting studies 
All the thermal denaturation profiles were obtained with a Kontron Uvikon 940 spectrophotometer as described 
[36]. The temperature of the thermal bath was increased or decreased at a rate of 0.2 °C/min, thus allowing 
complete thermal equilibrium of the cells. The experiments with the standard triplex 14C3 were performed in a 
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10 mM sodium cacodylate (pH 6.2) with 100 mM NaCl and the following oligonucleotide concentrations: 1.5 
µM for 36R and 36Y, 1.8 µM forthe third strand 14C3 and 6 µM cryptolepine [15]. 
UV melting studies on dialysis sequences were carried out in the dialysis buffer (15 mM sodium cacodylate, 10 
mM MgCl2 and 185 mM NaCl, pH 6.5) at 1.5 µM strand concentrations (equivalent to 19.5 µM in base triplets) 
and 6 µM cryptolepine. The concentration in base triplets was 19.5 µM for poly(dA)/2poly(dT) with 6 µM of 
cryptolepine. The poly(dA)/2poly(dT) was also tested in different buffer conditions (10 mM sodium cacodylate 
and 100 mM NaCl (pH 6.2) and 5 mM MgCl2) and cryptolepine concentration (3 µM). For all the experiments, a 
540 nm wavelength control was registered and the denaturation of the complex was followed at 260 and 295 nm 
(for DNA) and 366 and 379 nm (for cryptolepine). 
2.7.  TRAP assay 
The TRAP reaction was performed as previously described [37] in a 20 mM Tris HC1 pH 8.3 buffer containing 
63 mM KC1, 1.5 mM MgCl2, 1 mM EGTA, 0.005% Tween 20, 0.1 mg/ml BSA, 50 µM dTTP, dGTP and dATP, 
10 µM dCTP, 0.1 µg of the TS (5'-AATCCGTCGAGCAGAGTT-3 ') and CX primers, 5 ng of the NT primer, 
(5'-ATCGCTTCTCGGCCTTTT-3') 0.05 ng of the TSNT primer                                                                         
(5'-ATTCCGTCGAGCAGAGTTAAAAGGCCG-AGAAGCGAT-3'), 2 units of Taq polymerase, 2 µCi/tube of 
dCTP32 and 200 ng of A549 CHAPS extracts. After telom-erase elongation for 15 min at 30 °C, 30 cycles of 
PCR were performed (94 °C 30 s, 50 °C 30 s and 72 °C for 90 s). Telomerase extension products were then 
analysed on a non-denaturing 12% polyacrylamide 1X Tris Borate EDTA (TBE) vertical gel. 
Fig. 2. Equilibrium dialysis. All the measurements were performed in a 185 mM NaCl, 10mM MgCl2, 15 mM 
Na-cacodylate buffer (pH 6.5). The nucleic acid names are given on the left and all the structures are described 
in Section 2 and in Table 1. (A) Cryptolepine. (B) Neocryptolepine. 
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3.1. Equilibrium dialysis 
To evaluate the selectivity of cryptolepine and neocryptol-epine for different DNA structures, we performed a 
competitive dialysis experiment using 19 nucleic acid structures (described in Section 2) against a common 
(neo)cryptolepine solution. More products accumulate in the dialysis tube containing the structural form with the 
highest ligand binding affinity. It is possible to correlate the amount of the bound dye to a given structure with 
the affinity of the dye for that sample. As shown in Fig. 2A, cryptolepine interacts preferentially with duplex and 
triplex structures, whereas it shows a weak affinity for i-motif, single strands and a moderate affinity for G-
quadruplexes. For cryptolepine (Fig. 2A) and neocryptolepine (Fig. 2B), poly(dA)/2poly(dT) appears to be the 
preferred structure. A comparison of the binding affinity of cryptolepine for different duplexes indicates a 
preference for poly d(G-C) and ct-DNA, whereas pSD, ds26 and 24CTG show much weaker binding. In 
agreement with a recent report, cryptolepine interacts preferentially with GC than AT sequences [9]. Dialysis 
equilibrium experiments also present evident differences in DNA affinity between neocryptolepine and 
cryptolepine, confirming previous results [7]. The binding profile of the two compounds relative to higher-order 
DNA structures was quite unexpected and prompted us to confirm this interaction using different techniques. 
3.2. Mass spectrometry 
The ability of mass spectrometry to investigate drug-DNA interactions has been reviewed recently [38,39]. The 
binding stoichiometry, the relative binding affinities and the binding constants for DNA double helices of 
various sequences may be determined [34] and DNA complexes with intercalators and minor groove binders 
have been studied [40,41]. DNA triplex and quadruplex structures may also be investigated by electrospray mass 
spectrometry [33]. The affinity of cryptolepine and the parent isomer neocryptolepine for various DNA forms 
was therefore analysed by electrospray mass spectrometry (ESI-MS). In the present study, three 12 base pair 
duplexes with different GC content, three quadruplexes d(G4T4G4)2, d(TG4T)4 and the human telomeric sequence 
d[(G3T2A)G3] (reminiscent of tetraplexes 24G20 and 22AG used in the equilibrium dialysis assays) and one 
triple helical DNA structure (referred to as triplex) were studied. Fig. 3 shows the MS spectra obtained with the 
triplex (see Section 2 for details), the (TG4T)4 quadruplex and the Dickerson dodecamer duplex 
d(CGCGA2T2CGCG)2, with cryptolepine. A mixture of 1:1 and 2:1 drug-DNA complexes were detected with all 
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the sequences (also some 3:1 complexes with the triplex). The largest amount of complex is observed with the 
triplex, followed by the duplex. The amount of drug bound per quadruplex is lower than that for the other two 
structures. However, in order to allow the comparison with dialysis experiments, the amount of drug bound was 
expressed in terms of monomelic unit: the amount of bound drug calculated with Eq. (1) is divided by 14,12,and 
4 for the triplex, duplex, and quadruplex, respectively. Fig. 4 summarizes these results for cryptolepine and 
neocryptolepine. The latter has a much lower affinity than the former for all DNA structures, but shows the 
largest discrimination between the triplex and the other DNA structures. Both the drugs interact preferentially 
with a duplex containing a high GC content as expected for these intercalators [7]. The ESI-MS results agree 
well with the equilibrium dialysis results and these two independent methods lead to an identical conclusion: a 
preferential binding of cryptolepine to triple helical DNA. To our knowledge, this is the first report of a drug-
triplex interaction detected and quantified by electrospray mass spectrometry. We then wanted to confirm this 
interaction using spectroscopic techniques. 
3.3.  Triplex binding 
Using UV-absorbance melting studies on the 14C3 system, we observe a triplex stabilization of 3 and 5 °C at 6 
and 15 µM cryptolepine, respectively, in a 10 mM sodium ca-codylate and 100 mM NaCl pH 6.2 buffer. Under 
identical conditions, a relatively weak stabilization of a 21 base pair long telomeric duplex (ΔTm = 3 °C) was 
observed at 8 µM (data not shown). 
We then performed experiments on triplex sequences used in the dialysis experiments with the same buffer (15 
mM sodium cacodylate, 10 mM MgCl2, and 185 mM NaCl, (pH 6.5)). For the (T,C) (G,A) and (G,T) triplexes, 
the denatur-ation profiles did not significantly change in the presence of 6 µM cryptolepine. With regard to the 
poly(dA)/2 poly(dT) triplex, we observed two transitions without cryptolepine with a Tm of 65 and 75 °C, 
corresponding to the triplex and duplex dissociation, respectively. In the presence of 3 µM cryptolepine, only 
one transition is observed with a Tm of 75 °C (not shown). We performed this experiment in different buffer 
conditions (10 mM sodium cacodylate, 100 mM NaCl (pH 6.2) and 5 mM MgCl2) and cryptolepine 
concentration (3 µM). Again, we observed two transitions without cryptolepine (Tm = 68 and 75 °C) and only 
one with the dye (Tm = 75 °C) (Fig. 5). Two hypotheses arise: either cryptolepine completely prevents triplex 
formation or stabilizes it (i.e. the first transition is merged with duplex melting). Two reasons favour the second 
hypothesis. First, the spectra of cryptolepine with poly(dT) and the duplex poly(dA)/poly(dT) show no 
significant differences at high and low temperatures, whereas we observed a change with the triplex revealing an 
interaction between the dye and the DNA triplex at low temperature (Fig. 6). Second, the sum of the amplitudes 
of the two transitions corresponds to 0.15 OD without cryptolepine (0.1 for duplex and 0.05 for triplex). The 
amplitude of the duplex transition with cryptolepine is 0.1 OD, whereas the triplex poly(dA)/2poly(dT) transition 
leads to a hyper-chromism of 0.15. If cryptolepine prevents triplex formation, no difference in amplitudes should 
be observed. Therefore, we can conclude that cryptolepine significantly stabilizes (ΔTm = 10 °C) the 
poly(dA)/2poly(dT) triplex. An absor-bance titration of cryptolepine by the poly(dA)/2poly(dT) triplex was then 
performed in a 100 mM NaCl, 5 mM MgCl2, 10 mM cacodylate (pH 6.2) buffer. The interaction between 
cryptolepine and the poly (dA)/2poly (dT) triplex is evidenced by a modification of the absorbance spectrum of 
the dye. A slight red-shift in the absorbance peak at 368 nm is associated with a significant decrease in the 
extinction coefficient (data not shown). 
3.4. Quadruplex binding 
Dialysis and mass spectrometry experiments suggest that cryptolepine interacts with quadruplexes. To confirm 
this observation, we performed a UV-visible titration of cryptolepine (10 µM) with increasing amounts of 22 AG 
(0-12 µM). This oligonucleotide mimics the repeats of the human telomeric motif, and may adopt an 
intramolecular quadruplex structure [42,43]. This titration was performed in the presence of 0.1 M KC1, i.e. 
under conditions that strongly favour quadruplex formation (Fig. 7). 
The progressive modification of the absorbance spectrum of cryptolepine demonstrates an interaction with the 
preformed G-quadruplex. A slight red-shift in the absorbance peak at 368 nm is associated with a significant 
decrease in the extinction coefficient (=50%). A near isobestic point is obtained at 375 nm. However, no 
isobestic point is observed at around 400 nm, demonstrating that the binding process is complex and involves 
more than one binding mode. The absorbance values as a function of 22AG concentrations are shown in Fig. 7B. 
The shape of the titration curve suggests a relatively modest binding affinity (in the 105 M-1 range). The presence 
of several binding modes with different spectral properties (in agreement with the 1:1 and 2:1 complexes 
evidenced by MS) prevents a more precise analysis of the data. 
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We monitored by FRET the melting temperature of a G-quadruplex (5' GGGTTAGGGTTAGGGTTAGGG-3' 
representing the human telomeric motif) in the presence of various concentrations of cryptolepine. The melting 
temperature of a G4-forming fluorescent oligonucleotide may be recorded in the presence of various 
concentrations of the ligand [35,44]. At 1 µM cryptolepine, there is no significant stabilization of the G-
quadruplex, but a weak stabilization (ΔTm = 3 °C) is observed at 3 µM (data not shown). In order to confirm 
these results, fluorescence melting assays with 1-3 µM cryptolepine were also performed under different ionic 
conditions: the equilibrium dialysis assay buffer (15 mM sodium cacodylate, 10 mM MgCl2 and 185 mM NaCl, 
pH 6.5), the mass spectrometry buffer (0.1 M ammonium acetate) strongly favour quadruplex formation (0.1 M 
KC1). In all the cases, the stabilization was found to be 0-1.5 °C at 1 µM cryptolepine and between 1 and 4 °C at 
3 µM dye concentration (data not shown). These results are in agreement with the equilibrium dialysis and 
absorbance measurement, which indicates that the interaction of cryptolepine with the quadruplex-forming-
oligonucleotides is relatively weak. No significant stabilization is observed with neocryp-tolepine derivatives 
even at 3 µM. 
Fig. 3. Mass spectrometry. ESI-MS spectra of mixtures of 10 µM cryptolepine with (A) the triplex 
d(CCTTTTCTCTTTCC). d(GGAAAGAGAAAAGG)*d(CCTTTCTCTTTTCC). (B)the parallel quadraplex 
d(TG4T)4. (C) the dodecamer duplex d(CGCGA2T2CGCG)2. Each structure was tested at a concentration of 5 
µM. Spectra were recorded using the Q-Tof ultima Global. 
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Fig. 4. Mass spectrometry. Amount of ligand bound (µM) to each monomeric DNA structure determined by ESI-
MS. (A) Cryptolepine. (B) Neocryptolepine. 
 
 
3.5. Telomerase inhibition 
Telomerase inhibition efficiency was measured by a TRAP assay. The non-folded, single-stranded form of the 
primer is required for optimal telomerase activity and qua-druplex formation has been shown to directly inhibit 
telomerase elongation in vitro [20]. A growing number of small molecules have been discovered to inhibit 
telomerase activ ity by inducing and/or stabilizing G-quartet structure [45,46], including l0H-indolo [3,2-b] 
quinoline derivatives [47]. Therefore, here, we performed a TRAP assay with increasing concentrations (ranging 
from 1 to 50 µM) of the compound. Cryptolepine inhibits telomerase with an IC50 of 9.4 µM (Fig. 8). The 
presence of an internal control (ITAS) discriminates the inhibition of Taq polymerase during PCR amplification 
and telomerase elongation. A weak inhibition of the ITAS is detected up to 5 µM before telomerase elongation. 
It may reflect the preference of cryptolepine for a duplex than a G-quadruplex structure. This IC50 (in the 10 µM 
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range) is relatively modest when compared to the best G4-based telomerase inhibitors described, and reflects a 
relatively weak interaction with G-quadruplexes. No significant telomerase inhibition is observed with 
neocryptolepine derivatives (IC50 > 40 µM for all the compounds), in agreement with the absence of G-
quadruplex stabilization. 
Fig. 5. Denaturation profiles obtained for the poly(dA)/2poly(dT) triplex in the absence (solid line, triangles) or 
in the presence of cryptolepine (3 µM, dotted line, circles). Absorbance values were recorded at 260 nm. 
Experimental conditions: 10 mM sodium cacodylate, 5 mM MgCl2 and 100 mM NaCl (pH 6.5). 
 
 
Fig. 6. Absorbance differential spectra of cryptolepine in the presence of poly(dT) (triangles), poly(dA)/poly(dT) 
duplex (dotted line, circles) and poly(dA)/2poly(dT) triplex (squares). Experimental conditions: 10 mM sodium 
cacodylate, 5 mM MgCl2, 100 mMNaCl (pH 6.2) and 3 µM cryptolepine. 
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Fig. 7. Absorbance titration of cryptolepine by a G4-forming oligonucleotide. (A) Absorbance spectra of 10 µM 
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Fig. 8. Telomerase inhibition by cryptolepine in a TRAP assay. Increasing concentrations of cryptolepine were 
added in the TRAP mixture in the presence of an internal control (ITAS). TRAP activity was determined with 200 
ng of a CHAPS extract of A549 cell line. An IC50 of 9.4 µM was determined. 
 
4. Discussion 
In this paper, we have used several methods to study the interaction of the antimalarial drug cryptolepine with 
unusual DNA structures. This compound binds to G-quadruplexes, as demonstrated by dialysis, mass 
spectrometry, absorbance titration and FRET studies. However, its binding affinity is very modest. Cryptolepine 
stabilizes the F21MB quadruplex by 3 °C at 3 µM, whereas the best G4 ligands stabilize by 20 °C or more at 1 
µM compound [44]. It is not a potent telomerase inhibitor (IC50 = 9.4 µM); the best inhibitors described so far 
have an IC50 of 50 nM or lower [37,44,48-50]. 
The competition dialysis provided us with data on the affinity of the dye for triplexes, quadruplexes, duplexes 
and single strands. We confirm the observation that cryptolepine preferentially binds to poly d(GC) rather than to 
poly d(AT). DNA or RNA single strands are not good substrates for cryptolepine and no fixation on these 
structures has been observed. Interestingly, oligonucleotides which form an i-motif are cytosine-rich, but are not 
good substrates for cryptolepine despite its affinity for non-alterning cytosine-rich duplexes. Neocryptolepine 
exhibited a lower global affinity for DNA than cryptolepine, as shown by equilibrium dialysis and mass 
spectrometry. This observation may be related to the reduced cytotoxicity of neocryptolepine and its derivatives 
as compared to cryptolepine [25]. These molecules are developed as selective antimalarial agents and should not 
exhibit pronounced DNA interactions. 
Mass spectrometry may also be used to obtain relative affinities for various structures. To our knowledge, this is 
the first time the both the techniques (MS and competition dialysis) were compared. These assays gave 
qualitatively similar results (i.e. preference for triplexes, and global higher binding of cryptolepine as compared 
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to neocryptolepine). Some differences were nevertheless evidenced. Within the quadru-plex family, equilibrium 
dialysis suggests roughly equivalent affinities for the antiparallel (22AG) and parallel (24G20) structures, 
whereas MS results demonstrate a preferential binding to the antiparallel quadruplex ((GGGTTA)3GGG) as 
compared to the parallel [TGGGGT]4 structure. Further experiments using identical oligomers will be required in 
order to determine whether these differences are artefactual or caused by different experimental conditions. 
Interestingly, cryptolepine derivatives displayed good affinity for triplexes and we carried out further 
experiments using UV-melting studies and UV-absorbance titration. We show here that cryptolepine is a novel 
poly(dA)/2poly(dT) triplex ligand leading to a stabilization of 10 °C. Therefore, cryptolepine constitutes a novel 
triplex stabilizing agent. Several compounds like a tricationic cyanine dye [51] or neomycine [52] have already 
been described as poly(dA)/2poly(dT) triplex ligands. Interestingly, a structural similarity can be established 
between cryptolepine and the tetracyclic benzopyridoindole compounds BePI and BgPI which potently stabilize 
triplex DNA structures [15,53]. The carbazole moiety of cryptolepine, also present in the BePI/BgPI-type 
compounds as well as in another triplex-stabilizing agent NB506 [29], likely represents a key structural element 
for triplex binding. This study also adds cryptolepine to the growing list of topoisomerase I or II inhibitors which 
are also triplex-stabilizers [29,54,55]. The basis of a possible correlation between triplex binding and 
topoisomerase inhibition is certainly unclear. It might be linked to possible structural similarities between triplex 
DNA and a specific binding site for cryptolepine within the Topoisomerase-DNA complex. 
In conclusion, equilibrium dialysis and mass spectrometry may be used to analyse the structural selectivity of 
nucleic acid ligands, such as cryptolepine derivatives. Recent reports have shown that some molecules thought to 
be quadruplex-specific are rather triplex-specific [30]. The cryptolepine derivatives presented here exhibit a 
significant preference for triplexes over quadruplexes or duplexes. 
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